Has Meagan Dunne, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,999 in general payments to Meagan Dunne, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meagan Dunne, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meagan Dunne, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meagan Dunne, MD

Urology · Towson, MDNPI 1003295353

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,450 of the $30,999 with a category attached, or 85.3%. Boston Scientific accounts for 96.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $27,191 and has fallen 97.5% since, to $674 in 2025. Among urology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,999in general payments, 2019–2025

Across 92 payments — averaging $336.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$30K
Sumitomo Pharma America, Inc.$179
Teleflex LLC$168
Johnson & Johnson$160
Medtronic$130
Ferring Pharmaceuticals Inc.$129
plus $430 from 11 others

What the payments were for

Consulting fees$26,45085%
Food & beverage$4,54915%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	50	$29,804
Sumitomo Pharma America, Inc.	8	$179
Teleflex LLC	2	$168
Johnson & Johnson	10	$160
Medtronic	2	$130
Ferring Pharmaceuticals Inc.	2	$129
Urogen Pharma, Inc.	2	$99
Urovant Sciences Inc	5	$86
Axonics, Inc.	2	$62
Blue Earth Diagnostics	2	$47
AbbVie	1	$27
Progenics Pharmaceuticals, Inc.	1	$21
Olympus America Inc.	1	$20
Bioprotect Medical, Inc.	1	$19
Endo USA, Inc.	1	$18
Merck	1	$17
Acerus Pharmaceuticals Corporation	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL VASCULAR ACCESS$26,000
LithoVue$1,003
GENERAL KIDNEY STONE DISEASE$683
LITHOCLAST$388
Swiss LithoClast Triology$284
Lumenis Pulse 100H$154
UroLift$139
Re-Entry Malecot Nephrostomy Catheter Set$125
SWISS LITHOCLAST TRILOGY$120
EMS SWISS LITHOCLAST TRIOLOGY$117
NOCDURNA$111

How this compares

$30,999 in reported general payments places this provider in the 90th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland →

Medicare billing

Part B allowed, 2024

$179,164

Medicare patients

234

Services billed

1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Potassium Citrate ErPotassium Citrate	273	$21,049
MyrbetriqMirabegron	17	$11,803
Cefdinir	90	$795
Oxybutynin Chloride ErOxybutynin Chloride	53	$428
Tamsulosin Hcl	97	$381
Chlorthalidone	11	$174
Ondansetron OdtOndansetron	47	$155
Oxycodone Hcl	60	$139

Paid to pharmacies, not to this prescriber.

Other urology in Towson

Jonathan RubensteinTowson$15K
Benjamin CohenTowson$13K
Marc SiegelbaumTowson$12K
Matthew AllawayCumberland$20.6M
Benjamin LowentrittBaltimore$549K
Julio DavalosGlen Burnie$490K
Sankar KausikBel Air$375K
Laura GiustoOwings Mills$367K
Amin HeratiBaltimore$160K
Rian DicksteinHanover$144K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →